Who is sponsoring NCT05508113?

NCT05508113 is sponsored by Mengmeng Chen.

What drugs are being tested in NCT05508113?

Interventions in NCT05508113: ozone autohemotherapy.

What condition does NCT05508113 study?

NCT05508113 studies Post-ischemic Stroke Insomnia.

Is NCT05508113 still recruiting?

NCT05508113 is currently status unknown. Last updated 22 August 2022.

Last reviewed 2022-08-22 · How we verify

NCT05508113

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ozone Autohemotherapy for Ischemic Stroke Sleep Disorder

Status unknown NA Last updated 22 August 2022

What this trial tests

NA trial testing ozone autohemotherapy in Post-ischemic Stroke Insomnia in 60 participants. Status unknown.

Timeline

26 August 2022

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Mengmeng Chen
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	supportive care
Enrollment	60
Start date	26 August 2022
Primary completion	31 December 2022
Estimated completion	31 December 2022

Drugs / interventions tested

ozone autohemotherapy

Conditions studied

Post-ischemic Stroke Insomnia — all drugs for Post-ischemic Stroke Insomnia →

Sponsor

Mengmeng Chen

Who can join

Eligibility, any sex, with Post-ischemic Stroke Insomnia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to observe the efficacy and safety of ozonated autohemotherapy in patients of post-ischemic stroke insomnia and to explore its mechanism of action.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05508113 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mengmeng Chen
Last refreshed: 22 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05508113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing